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OBJECTIVES: Hereditary angioedema (HAE) is a rare and potentially life-threaten-
ing condition. The efficacy of acute HAE treatments has not been assessed in head-
to-head comparative studies. This study aimed to establish the relative efficacy of
icatibant [Shire HGT] versus C1-esterase inhibitor concentrate (C1-INH) [CSL Beh-
ring], C1-INH [ViroPharma], rh-C1-INH [Pharming], and ecallantide [Dyax].
METHODS: A systematic literature review identified nine relevant randomised
clinical trials. Indirect comparison (IC) hazard ratios (HR) between treatments were
calculated using the methods of Bucher et al (1997) and Song et al (2003). To account
for trial heterogeneity, five sets of icatibant data were considered separately; three
clinical endpoint definitions (time to onset of primary symptom relief, time to
initial symptom improvement [subject-assessed], and time to onset of symptom
relief based on composite VAS score); and three rescue medication (RM) censoring
methods (no censoring [RMs ignored], censoring subjects who took RMs prior to
onset of symptom relief, and resetting time to onset of symptom relief to 24 h for
censored subjects) were considered separately in the ICs. RESULTS: The IC consid-
ered each of the 45 icatibant data/endpoint definition/RM censoring combinations.
HR estimates favoured (HR 1) 37/45 icatibant combinations versus C1-INH [CSL
Behring] 20 IU/kg (Median HR  1.39 [minimum 0.72, maximum 2.10]), 45/45 (29
statistically significant) versus C1-INH [CSL Behring] 10 IU/kg (Median HR  2.19
[minimum 1.07, maximum 3.39]), 32/45 versus C1-INH [ViroPharma] (Median HR 
1.36 [minimum 0.63, maximum 2.22]), 24/45 versus rh-C1-INH 50 IU/kg (Median HR
 1.04 [minimum 0.48, maximum 1.70]), and 43/45 versus ecallantide (Median HR
1.67 [minimum 0.75, maximum 2.66]). CONCLUSIONS: Icatibant showed improved
time to symptom relief when compared with C1-INH [CSL Behring] 10 IU/kg. No
clear differences were evident versus either C1-INH [CSL Behring] 20 IU/kg (SmPC
dosing) or the three other HAE treatments.
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OBJECTIVES: Due to limited patient population and scarcity of real-world data,
performing health economic analyses in haemophilia patients with inhibitors is
challenging. A recent publication based on national data from the Czech Republic
presented a health economic comparison of recombinant activated factor VII (rF-
VIIa) and plasma-derived activated prothrombin complex concentrate (pd-aPCC) in
the treatment of bleedings in inhibitor patients. The objective of this study was to
adapt the findings from the Czech study to a Swedish setting. METHODS: Aggre-
gated published data were used for the analysis. Real-life resource utilization (by-
passing agents and hospitalizations) were derived from the Czech study. Swedish
costs were obtained by multiplying each resource with corresponding unit costs
obtained from public price lists. RESULTS: Mean dose per bleeding in the rFVIIa
group was 17000 mcg, while the corresponding figure for the pd-aPCC group was
23000 IU. Mean number of hospital days was 0.9 in the rFVIIa group and 3.2 in the
pd-aPCC group. Mean total cost per bleeding was almost twice as high in the pd-
aPCC group (SEK 225549) compared to the rFVIIa group (SEK 112298). There was a
large variability in resource use across bleeding episodes in both treatment groups.
CONCLUSIONS: The Swedish adaptation of the Czech health economic analysis of
rFVIIa and pd-aPCC showed that rFVIIa treatment was associated with substan-
tially lower costs per bleeding episode. The main limitation of this analysis in a
Swedish setting is that it is based on data from the Czech Republic. However, Czech
data should have relevance in a Swedish setting, considering the large similarities
between the countries regarding incidence and severity of the disease, manage-
ment of haemophilia, availability of health care resources, clinical practice pat-
terns, and relative prices. A strength of the analysis is that it is based on real-life
data.
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OBJECTIVES: Innovative treatments have transformed CML into a chronic disease
mostly managed in outpatient care. This study aimed to estimate the cost of treat-
ing patients with CML as well as the cost of managing the adverse events of the
disease. METHODS: A retrospective study was performed in the Heamatology De-
partment of Evangelismos General Hospital of Athens. Study sample consisted of
all patients (n79) who visited the hematology of outpatient Units of the hospital
from January 2007 to December 2011. Cost analysis was based on patient’s direct
cost, including cost of personnel, supplies, medication, laboratory and imaging
tests, infrastructure and various other on-site costs. Mean annual cost per patient
is elaborated separately in outpatient and inpatient care. Inpatient costs mostly
refer to the treatment of adverse events. Cost analysis is based on each year’s NHS
prices transformed in 2012 values and the National Health System (NHS) persective
has been used. RESULTS: The mean annual cost per patient in chronic phase of
Myeloid Leukemia treated in outpatient care is estimated at €22.972. The most
frequent adverse events managed were anemia (n7, 9% of patients) and neutro-
penia (n12, 15% of patients). Mean hospitalization cost per patient due to the
treatment of adverse events is as follows: for anemia €2.193 and neutropenia of
€1.312. The cost of treating anemia corresponds to 9.5% of the overall cost of treat-
ment and the cost of neutropenia about 5,7%. Annual cost of newly diagnosed
patients in 2011 was estimated at €8.339, 57% lower than the respective cost of
patients treated in 2007 (€14.652). CONCLUSIONS: Innovative treatments for CML
have resulted in treating patients in outpatient care with lower adverse events and
consequently lower cost. Under the current economic restriction Greece is facing
as well as the recent implementation of Diagnoses Related Groups, information on
treatment costs provides a tool to assess NHS hospitals’ performance.
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OBJECTIVES: To analyze the direct and indirect cost of therapy of chronic myeloid
leukemia (CML) from the society perspective within one year. METHODS: It is a
prospective observational cost study of 36 patients treated at the University Hos-
pital “Alexandrovska”. The pharmacotherapy cost, GP and specialists visits cost,
hospitalization cost were collected as direct medical costs. National health insur-
ance fund and hospital tariff were used as unit cost sources. Days out of work were
also collected and multiplied with the average monthly income to gather the indi-
rect costs. RESULTS: The observed 36 patients (average age 51 years) remain 14% of
all diagnosed and actively treated CML population. Average monthly cost of ther-
apy is 3130 Euro (SD 775 Euro) thus reaching 37 560 Euro per year per patient. On
imatinib therapy were found 20 of the observed patients, 8 on dasatinib, and 2 on
nilotinib. 6 patients were switched to different medicine during the period, out of
them 5 from imatinib to nilotinib due to disease progression and 1 from imatinib to
dasatinib due to intolerance development. On average 5 visits were performed per
year to GP and from 4-12 to specialists. The cost of the respective visits is 18 (SD5),
and 34 euro per patient. Only 6 patients were hospitalized during the therapy
switch and their cost was found to be 1098 Euro. The total number of days out of
work was found to be 103 days for the employed patients thus consuming incomes
for 5 months. Relative share of the direct and indirect cost is 92% to 8%, respec-
tively. Out of the direct medical cost medicines account for near 90%.
CONCLUSIONS: CML consumes mainly direct medical costs where the medicines
are the main cost driver.
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OBJECTIVES: Acute Myeloid Leukaemia (AML) can be diagnosed at any age and
accounts for approximately one third of all leukaemia diagnoses. Treatment,
which can be given with supportive and/or curative intent, is considered expensive
compared to other cancers. Despite this, no long-term predictive models have been
developed for AML, mainly due to the complexities associated with this disease.
Thus, the aim of the current study was to develop an AML model (based on a UK
cohort) that would allow cost and life expectancy results to be expressed at popu-
lation level. METHODS: The model developed in this study combined a decision
tree with several Markov models. This was in order to reflect the complexity of
health states, treatments, and prognostic factors (such as age and response to
chemotherapy) of AML. The model was simulated over a life cycle of 60 months and
results were contrasted between two age-groups and over different treatment
pathways. Probabilistic modelling was also implemented in order to capture the
potential uncertainties of input parameters. Transition probabilities, life expectan-
cies and costs were derived from the NHS Hospital Episode Statistics (HES) and a UK
population-based database from the Haematological Malignancy Research Net-
work (HMRN, www.hmrn.org). RESULTS: The expected five year medical cost and
life expectancy for the elderly patients (60) were £22,538 and 8.5 months respec-
tively, and for the young adult patients (18-60) £82,266 and 33.78 months respec-
tively. The model was validated by the fact that the predicted results captured 92%
of the actual costs, while it also demonstrated good fit of the actual survival
outcomes. CONCLUSIONS: Costs and life expectancy of AML vary according to
patient characteristics and treatment pathways. It is expected that future applica-
tion of the AML model developed in this study could be used to evaluate new
diagnostic tools/treatments and to support health care decision makers.
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OBJECTIVES: To quantify the work productivity loss induced by chronic immune-
mediated inflammatory diseases. METHODS: A systematic and computerized
search was performed in the literature published in English from 2000 to 2011 in
Pubmed. The search terms were: ‘crohn disease’, ‘spondylitis, ‘ankylosing’, ‘psori-
asis’, ‘rheumatoid arthritis’, ‘work productivity’, ‘productivity’, ‘absenteeism’, ‘sick
leave’ and ‘employment status’. Number of days of absenteeism and presenteeism,
and their estimated costs were extracted. Mean duration of work productivity loss
per patient was annualized. Mean costs per patient were annualized, converted in
Euros and actualized to 2010 using exchange rates and price indexes provided by
the Organisation for Economic Co-operation and Development. RESULTS: Eighteen
publications were analyzed: 4 for rheumatoid arthritis, 6 for ankylosing spondyli-
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tis, 5 for psoriasis and 3 for Crohn’s disease. Available information for each condi-
tion is presented hereafter. In rheumatoid arthritis, absenteeism ranged from 25 to
56 days per year and presenteeism was estimated to 55 days. The mean cost of
absenteeism in this condition ranged from €709 to €10,166. In ankylosing spondy-
litis, annual absenteeism ranged from 6 to 65 days, which represented €726 to
€2,532 per patient. Presenteeism was estimated to 14 days loss with an associated
annual cost of €1,027. In psoriasis, annual absenteeism ranged from 3 to 14 days
and presenteeism from 16 to 35 days. The costs of work productivity loss (absen-
teeism  presenteeism) in psoriasis ranged from €1,675 to €6,300. In Crohn’s dis-
ease, annual absenteeism was of 120 days per patient in median, which repre-
sented a cost of €4,745. No data on presenteeism was found. CONCLUSIONS:
Chronic immune-mediated inflammatory diseases have a high impact on work
productivity loss due to both number of days at work lost and decreased perfor-
mance with substantial costs.
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OBJECTIVES: To assess the improvement in work productivity associated with
adalimumab therapy in chronic immune-mediated inflammatory diseases.
METHODS: A systematic and computerized search was performed in the literature
published in English from 2000 to 2011 in Pubmed. The search terms were: ‘crohn
disease’, ‘spondylitis, ankylosing’, ‘psoriasis’, ‘rheumatoid arthritis’, ‘work produc-
tivity’, ‘productivity’, ‘absenteeism’, ‘sick leave’, ‘employment status’ and ‘adali-
mumab’. Questionnaires used to measure the work productivity were identified.
Results were annualized and costs converted in Euros and actualized to 2010 using
exchange rates and price indexes provided by the Organisation for Economic Co-
operation and Development. RESULTS: Nine clinical trials and one meta-analysis
were analyzed: 5 in rheumatoid arthritis, 1 in ankylosing spondylitis, 3 in psoriasis
and 1 in Crohn’s disease. Work Productivity and Activity Impairment (WPAI) ques-
tionnaire was used in 62% of studies. In rheumatoid arthritis, adalimumab was
associated with a 8-to-21-working day per year decrease in absenteeism and an
8-to-10-day decrease in presenteeism. In ankylosing spondylitis, adalimumab was
associated with a decrease of 8 working days per year in absenteeism and a 50 day
decrease in presenteeism. In psoriasis, adalimumab was associated with a de-
crease of 27 days in presenteeism but no significant improvement of absenteeism
was observed in this condition. In patients with moderate to severe Crohn’s dis-
ease, treatment with adalimumab was associated with a 18 working day per year
decrease in absenteeism and a 47-day decrease in presenteeism. Costs saving re-
lated to increased global work productivity (absenteeism and presenteeism) were
estimated to €1,720 per patient per year in rheumatoid arthritis and €7,625 in
Crohn’s disease. CONCLUSIONS: Adalimumab provided clinically significant im-
provements in work productivity that could be associated with savings of to € 7,625
in improved work productivity in Crohn’s disease.
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OBJECTIVES: Immune thrombocytopenia (ITP) is an immunologic blood disorder
characterised by low platelet counts and bleeding. The management of ITP aimed
at minimising bleeding events. Eltrombopag is an oral thrombopoietin receptor
agonist indicated as second line treatment of chronic ITP in adults. This economic
study estimated the direct costs of ITP management with eltrombopag in the
French setting. METHODS: A phase III clinical trial (RAISE) compared the response
to once daily eltrombopag versus placebo in adult patients with chronic ITP during
a 6-month period. Use of medical resources was assessed from the RAISE data
regarding eltrombopag dosage, treatment duration, bleeding-related events (BREs
grade 2), rescue therapy (IVIG, oral steroids), concomitant medications and hos-
pitalisations. The economic analysis was restricted to direct costs (2011 values)
measured in the perspective of the French Sickness Fund (full coverage for ITP).
RESULTS: For 6 months of treatment, total cost per patient receiving eltrombopag
(mean dose: 55.2mg) was estimated at 15,318 € with 88.9 % of the costs induced by
the main drug treatment. Monitoring costs related to eltrombopag (blood tests and
visits) were estimated at 403 € (2.6%). At least, concomitant drugs, BREs and rescue
therapy were respectively accounting for 623 € (4.1%), 730 € (4.8%) and 344 € (2.2%).
These results seem consistent with other French economic estimations concerning
patients treated with IVIG (13,291 €/6 months) or patient treated with romiplostim
(3g/Kg, 17,486 €/6 months). CONCLUSIONS: With the data from the RAISE clinical
trial, the direct cost for a patient treated with eltrombopag during a 6 months
period was estimated at 15,318 €. Estimation of direct costs may be envisaged in an
exploratory manner when Phase III clinical trials are close to real practice manage-
ment and has to be confirmed by collected resource utilization in observational
studies.
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OBJECTIVES: Day-to-day clinical practice outcomes and related costs are impor-
tant not only to confirm clinical trial results but also to inform more efficiently
clinical decision making. The objective of this retrospective study was to charac-
terize the main treatment outcomes and associated costs of a MDS and AML pa-
tient’s population in a hematology center in Portugal. METHODS: Adult patients
(n27) with MDS or AML at diagnosis and eligible for treatment with azacitidine at
any stage of their disease were eligible. Retrospective data was obtained from
hospital clinical records. Treatment outcomes included time-to-leukemia (TTL),
leukemia-free survival (LFS) and overall survival (OS). Survival analysis was per-
formed with the standard non-parametric Kaplan-Meier method. Costs were esti-
mated by multiplying resource utilization frequencies by their unit prices.
RESULTS: Mean follow-up was 15 months (min-max: 2.1-31.2). Mean (SD) age at
diagnosis was 67 (11) years. Nine patients (33%) were in IPSS risk intermediate-1
while the reminder (67%) were IPSS intermediate-2 or high. Median TTL, LFS and OS
were 20.4 months (95% CI: 11.3-NR), 15.3 months (95% CI: 11.0-20.4) and 17.2
months (95% CI: 14.1-29.8) respectively. Mean overall hospital related treatment
costs were 55,470€ per patient (min-max: 2,302€- 130,264€), an average (SD) of
4,017€ (1,593€) per month. CONCLUSIONS: Treatment outcomes in this population
are in the range of those reported in azacitidine clinical trials and other observa-
tional studies. Up to date effective management of MDS/AML is associated with
costly health care.
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OBJECTIVES:Oral anticoagulation therapy (OAT) with a vitamin K antagonist (VKA)
requires frequent monitoring of blood clotting, which involves great amounts of
time and costs. Newer technologies offer patients the possibility to perform home
monitoring of OAT. The objective of this study was to assess the economic impact
of patient self-management (PSM) of OAT compared with standard clinic monitor-
ing in a Canadian context. METHODS: A cost-consequence analysis was per-
formed, according to the perspective of the Province of Quebec health care system
and the societal perspective. A time horizon of one year of OAT monitoring was
chosen. Clinical data was obtained from a randomized Montreal Heart Institute
clinical trial by Verret et al., which compared clinical efficacy and quality of life
(QoL) of PSM versus standard monitoring. From the health care system perspective,
costs considered were those associated with test strips, physician visits, pharma-
cist time and patient training. From the societal perspective, the additional costs
associated with the acquisition of the monitoring machine, and time dedicated to
monitoring were considered. RESULTS: Annual costs per patient of 372.53 CAD$
and 397.27 CAD$ were associated with standard monitoring and PSM respectively
under the health care system perspective. Annual costs per patient were estimated
at 1,116.08 CAD$ for standard monitoring while annual PSM costs were estimated
at 533.19 CAD$ under the societal perspective. Both OAT methods were shown to be
clinically equivalent, however a significant improvement of QoL was found in PSM.
CONCLUSIONS: From the health care system perspective, PSM is slightly more
expensive than standard monitoring of OAT (24,74 CAD$), but from the societal
perspective PSM is associated with significant savings compared to standard mon-
itoring of OAT (-582.89 CAD$). Also, PSM is associated with improves patient’s QoL
while assuring the same monitoring quality as standard monitoring of OAT.
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OBJECTIVES: To assess the cost-effectiveness of prophylaxis vs on-demand ther-
apy with Anti Inhibitor Complex Concentrate (AICC). METHODS: Hemophilia A
patients 2 years with inhibitors and using bypassing therapy to treat bleeding
were recruited in a prospective, randomized, crossover study comparing 6 months
of AICC prophylaxis therapy with 6 months of on-demand therapy. The prophy-
lactic and on demand periods were separated by a 3-month washout. Cost evalu-
ation was based on direct (clotting factors, hospitalization, outpatient care, physi-
cians’ visit and other pharmacological therapy) and indirect (days of school/work
missed because of bleeding) costs, adopting the perspective of the third party
payer. Costs are expressed in US$ of 2011. We calculated the incremental cost per
bleeding avoided and the cost-effectiveness acceptability-curve. RESULTS: Twen-
ty-six patients were enrolled. The per-patient six-months cost during prophylaxis
period was 496,393 US$ compared with 211,330 US$ on on-demand. The incremen-
tal cost-effectiveness ratio in the prophylaxis vs on demand period was 34,852 per
bleeding event avoided. The acceptability curve showed there would be a 93%
likelihood that prophylaxis therapy would be considered cost-effective at willing-
ness-to-pay threshold of US$ 50,000 per bleeding event avoided. In Subjects with a
50% reduction in bleeding events, the incremental cost-effectiveness ratio in the
prophylaxis vs on demand period was US$ 25,877 per bleeding event avoided. In
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